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Summary Angiogenesis is recognized as an important step in tumour pathogenesis that is related to invasion and metastatic spread and
which consequently results in poor clinical outcome. In this study, we have examined the role of tumour stroma-activated fibroblasts and
macrophage infiltration in the development of the angiogenic and metastatic phenotype in non-small-cell lung cancer (NSCLC). A total of 141
cases of early stage I-Il NSCLC treated with surgery alone were analysed. The JC-70 (anti-CD31) MAb was used for the assessment of
vascular grade. The P-GF.44C MAb was used to assess thymidine phosphorylase (TP) reactivity in cancer cells, stromal fibroblasts and
macrophages. Cancer cell TP overexpression related to high vascular grade and to advanced T stage (P = 0.0004 and P= 0.02). Expression
of TP in stromal fibroblasts also correlated with high angiogenesis (P= 0.01), but was independent of cancer cell expression. Fibroblast TP
overexpression was related to abundant stroma (P= 0.003), suggesting that TP may be a marker of active stroma. Moreover, intense
macrophage infiltration was associated with fibroblast TP reactivity, regardless of the amount of stroma, suggesting that macrophages may be
a major contributor to TP expression in stroma. Survival analysis showed that cancer cell TP overexpression was related to poor prognosis (P
= 0.005). Although stroma TP is related to angiogenesis, in the low vascular grade group it defined a group of patients with better prognosis
(P = 0.02). It may be that fibroblast TP reactivity is an indirect marker of tumour infiltration by functional macrophages, which have an anti-
tumour effect. We conclude that stromal macrophage and fibroblast TP reactivity may have an important role in non-small-cell lung cancer
behaviour. Understanding the role of stromal fibroblasts and inflammatory cells and their interaction with oncoprotein expression is essential
for the elucidation of lung cancer pathogenesis.
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Tumour neoangiogenesis has been recently recognized to be of
importance in defining subsets of patients with poor outcome in
diseases such as breast, lung and other cancers (Weidner et al,
1991; Horak et al, 1992; Craft et al, 1994; Fontanini et al, 1995;
Giatromanolaki et al 1996 a,b). Understanding the mechanisms of
tumour angiogenesis could lead to new therapeutic strategies
based on antiangiogenic molecules (Scott et al, 1994). Several
growth factors, such as fibroblast growth factor (FGF), vascular
endothelial growth factor (VEGF) and platelet-derived endothelial
cell growth factor/thymidine phosphorylase, have shown angio-
genic properties (Klagsbrun et al, 1989; Ferrara et al, 1992;
Moghaddam et al, 1995). Immunohistochemical detection of their
expression in tissue samples has already been reported (Guidi et al,
1995; Takanami et al, 1996).
In previous studies, we investigated thymidine phosphorylase
(TP) expression in non-small-cell lung cancer and showed that TP
overexpression in cancer cells was correlated with high tumour
angiogenesis and poor prognosis (Koukourakis et al, 1997). In the
present study, we further analysed the role ofTP overexpression in
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stromal fibroblasts on non-small-cell lung cancer neoangiogenesis
and its impact on survival. We also examined macrophage tumour
infiltration as macrophages have been shown to be angiogenic in
several experimental systems and to express TP.
MATERIALS AND METHODS
We examined 141 tumour samples from patients with operable [(T1,
2-NO, 1 staged (Mountain et al, 1986)] non-small-cell lung cancer.
All patients were treated with surgery alone and survived at least 60
days after operation (to exclude perioperative mortality-related
bias). The median follow-up period was 30 months (2.4-7 years).
Histological diagnosis, grading and N staging were performed on
haematoxylin and eosin-stained sections. A total of 92 out of 141
(65%) were squamous cell carcinomas and 49 out of 141 (35%)
cases were adenocarcinomas. Lymph node involvement was present
in 50 out of 141 (35%) cases. Histological grade 11I was confirmed
in 65 out of 141 (46%) cases and grade III in 76 out of 141 (54%).
Assessment of vascular grade
The JC-70 monoclonal antibody recognizing CD31 was used for
microvessel staining on 5 tm paraffin-embedded sections using
the alkaline phosphatase-anti-alkaline phosphatase (APAAP)
method (Parums et al, 1990). Sections were dewaxed, rehydrated
and predigested with protease type XXIV for 20 min at 37°C.
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Figure 1 Different combinations of cancer cell (CCR) and fibroblast (FR) TP reactivity (A, CCR+/FR+; B, CCR+/FR-; C, CCR-/FR-). D shows a case with
negative tumour cell TP reactivity and high stromal macrophage infiltration. In E and F high fibroblast TP reactivity (E) associates with intense stromal
neoangiogenesis (F) in the absence of cancer cell TP staining
JC70 as undiluted supernatant was applied at room temperature for
30 min and washed in Tris-buffered saline (TBS). Rabbit anti-
mouse antibody 1:50 was applied for 30 min, followed by applica-
tion of mouse APAAP complex 1:1 for 30 min. After washing in
TBS, the last two steps were repeated for 10 min each. The colour
was developed by 20 min incubation with New Fuchsin solution.
Appraisal of stained microvessels with a Chalkley eyepiece
graticule at x 250 (0.155 mm2) defined two different vasculargrades:
high [Chakley score (CS) 7-12 vessels within the visual field] and
low (CS 2-6). This grouping was based on the results of a previous
study when two groups ofpatients with tumour CS 2-4 and 5-6 had
a similar prognosis, whereas a CS higher than 6 defined a group with
a significantly poorer prognosis (Giatromanolaki et al, 1996a).
TP immunohistochemistry and macrophage infiltration
assessment
TP expression was assessed with P-GF.44C monoclonal antibody
using a streptavidin-biotin peroxidase (Dako, UK) technique (Fox
et al, 1995; Giatromanolaki et al, 1997). Omission of the primary
antibody was used as a negative control. Alveolar macrophages
were used as a positive internal control (Giatromanolaki et al, 1997).
Tumour cell component was assessed for TP expression by the
intensity and extent ofstaining (Figure 1). Two staining patterns of
TP reactivity (TPR) were considered: low reactivity (<50% of
cancer cells stained or diffuse weak reactivity) and high reactivity
(strong staining in >70% cells). Strong staining in 50-70% ofcells
was observed in only 3 out of 141 cases and these cells were clas-
sified in the 'positive' group. Focal strong reactivity within a
general pattern of negative reactivity was observed in 27 out of
141 cases, but the extent of staining was never higher than 20% of
the sample. These focally TP-expressing cases were included in
the 'low reactivity' group.
Similarly, the degree of stromal fibroblast TPR was graded as
low (expression in 0-50% of fibroblasts or diffuse weak expres-
sion) and high (diffuse strong positivity of the stromal fibrobasts)
(Figure 1). The amount of stroma within the tumour was also
recorded as scarce (s) or abundant (a) after agreement of all three
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Table 1 Vascular grade correlation with other examined parameters in 141
cases of early stage non-small-cell lung cancer
Vascular grade
Parameter Low High P-value
T stage
Ti 34 14 0.99
T2 66 27
N stage
NO 78 13 0.0001
Ni 22 28
Histology
Squamous 63 29 0.44
Adenocarcinoma 37 12
Grade
l/ll 44 20 0.71
III 55 21
Tumour cells (TP reactivity)
Low 81 20 0.0004
High 19 21
Fibroblasts (TP reactivity)
Low 81 25 0.01
High 19 16
Stromal amount
Scarce 52 10 0.003
Abundant 48 31
Macrophage infiltration
Low 73 32 0.67
High 27 9
Table 2 Cancer cell thymidine phosphorylase reactivity correlation with
other examined parameters in 141 early stage non-small-cell lung cancer
TP cancer cell reactivity
Parameter Low High P-value
T stage
Ti 41 9 0.02
T2 60 31
N stage
NO 71 20 0.03
Ni 30 20
Histology
Squamous 66 26 0.99
Adenocarcinoma 35 14
Grade
l/ll 48 17 0.70
III 53 23
Vascular grade
Low 81 19 0.0004
High 20 21
Fibroblasts (TP reactivity)
Low 74 32 0.52
High 27 8
Stromal amount
Scarce 45 17 0.70
Abundant 56 23
Macrophage
Low 74 31 0.51
High 28 8
pathologists on the conference microscope (no quantitative criteria
were used). TP staining could also be used to assess the degree of
tumour infiltration by macrophages as low (LMI) and high (HMI)
(Figure IB). The presence of intense stromal and/or tumoral
infiltration with macrophages in more than 50% of the examined
optical fields was necessary to score the case as HMI. Again, the
decision was made on the conference microscope. In cases with
both intense fibroblast TPR and HMI, morphological criteria were
used to distinguish fibroblasts from macrophages and no disagree-
ment was noticed between observers, showing that in expert hands
the differential assessment of TPR in the stromal cellular compo-
nents is feasible. However, pure quantitative macrophage infiltra-
tion assessment (macrophage counting) in these cases could be
facilitated with double or further staining using anti-CD68 anti-
bodies (data not shown). The lymphocytic component (clearly
seen with the JC-70 staining) was never stained with TP.
Intra- and interobserver variability
Both vascular grade appraisal and TP (tumour cell and fibroblast)
assessment were examined for intra- and interobserver variability.
Three experienced observers assessed the slides separately and
repeated the assessment 10-30 days later. The final decision was
taken on a conference microscope. The second assessment highly
correlated with the first for all three observers (r = 0.91, P < 0.006,
for vascular grade and r = 0.96, P < 0.001, for TP). Similarly, the
three investigators' vessel grading and TP appraisal correlated
well with each other (r = 0.94, P < 0.001, and r = 0.91, P < 0.008,
respectively). Final decisions of a few controversial cases as well
as the degree of macrophage infiltration and amount of stroma
were made on the conference microscope.
Statistical analysis
Statistical analysis was performed using the Stata 3.1 Package
(Stata corporation, TX, USA). Survival curves were plotted using
the method ofKaplan and Meier, and the log-rank test was used to
determine statistical differences between life tables. A Cox propor-
tional hazard model was used to assess the effects of patient and
tumour variables on overall survival. Fisher's exact test was used
for testing relationships between categorical tumour variables.
Linear regression analysis was used to assess intra- and inter-
observer variability. A P-value < 0.05 was considered significant.
RESULTS
High vascular grade was observed in 41 out of 141 (29%) cases
and low in 100 out of 141 (71%). High TP tumour cell reactivity
was observed in 40 out of 141 (28%), and negative in 101 out of
141 (72%) of cases. Table 1 shows the correlation of vascular
grade with all of the other parameters examined. Lymph node
involvement was directly related to high vascular grade (P <
0.0001). High TPR of tumour cells as well as stromal fibroblasts
was also correlated with high vascular grade (P = 0.0004 and P =
0.01). Abundant stroma was associated with high vascular grade
(P = 0.003). None ofthe remaining parameters (T stage, histology,
grade or macrophage infiltration) showed any correlation with the
degree of vascularization.
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Table 3 Vascular grade and total thymidine phosphorylase tumour activity
(TTPA) in 141 early stage non-small-cell lung cancer
Tumour/stroma Vascular grade
TP reactivity
Low High P-value
A High/high 3 5 Avs Bvs C; P= NS
B High/low 16 16 A vs D;P = 0.0003
C Low/high 16 11 B vs D;P= 0.0001
D Low/low 65 9 C vs D;P= 0.001
A, B, C High TTPA 35 (52%) 32 (48%) P = 0.0001
D Low TPPA 65 (88%) 9 (12%)
Table 4 Correlation of the degree of macrophage infiltration with other
parameters examined in 141 early stage non-small-cell lung cancer
Macrophage infiltration
Parameter Low Ml High Ml P-value
Nodes
NO 62 29 0.04
Ni 43 7
Vascular grade
Low 73 27 0.68
High 32 9
Tumour cells (TP reactivity)
Low 74 27 0.39
High 31 9
Fibroblasts (TP reactivity)
Low 87 19 0.0003
High 18 17
Stromal amount
Scarce 44 18 0.27
Abundant 61 18
Cancer cell TP expression analysis
We further examined whether TP cancer cell expression correlated
with tumour and stromal parameters (Table 2). High vascular grade
was more frequent in TP-overexpressing tumours (P = 0.0004). The
difference was statistically significant for squamous cases (P <
0.0001), but not for adenocarcinomas. Cancer cell TPR was not
related to fibroblast TP expression, stromal amount or degree of
macrophage infiltration. High cancer cell TPR was more frequent in
largerT2-stage tumours (P = 0.02) andNl stage (P = 0.03), showing
atendency forTP to be expressed late in the course oftumourevolu-
tion. No correlation was found with histology and grade.
Stromal fibroblast analysis
Normal fibroblasts examined in 123 samples with normal lung
tissue were invariably negative for TP expression. Strong diffuse
TP fibroblast overexpression in the tumour stroma was observed
in 35 out of 141 (25%) and negative/weak staining in the
remaining 106 out of 141 (75%) cases.
Abundant stroma directly correlated with TP overexpression by
fibroblasts. A total of 30 out of 35 (86%) cases with fibroblast TP
overexpression had abundant stroma vs 49 out of 106 (46%) of
cases with low TPR (P = 0.0003).
Total thymidine phosphorylase reactivity
In Table 3 the vascular grade is analysed within four different cate-
gories defined aftercombination ofcancercell and stromal fibroblast
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Figure 2 Survival curves of 141 T1,2-NO,1 staged non-small-cell lung
cancer patients following the cancer cell TP reactivity patterns (CCR; A), the
stromal fibroblast TP reactivity patterns (FR; B) and the total thymidine
phosphorylase tumour reactivity (TPR; C). (A) - A, CCR- (101 pts); ----, B,
CCR+ (40 pts). A vs B, P= 0.005. (B) ----, A, FR- (106 pts); -, B, FR+
(35 pts), A vs B, P = 0.08. (C) -, A, Low TPR (74 pts); ----, B, high TPR (67)
AvsB, P=0.03
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Figure 4 Survival analysis in 81 low vascular grade cases with low TP
cancer cells reactivity. Stratification for fibroblast TP reactivity (FR) and
degree of macrophage infiltration (Ml) ----, A, FR+/LMI (3 pts); -, B,
FR+/HMI (13 pts); --, C, FR-/LMI (55 pts); - - -, D, FR-/HMI (10 pts). A, B
vs C, P = 0.06; A, B vs D, P = 0.001; C vs D, P=0.02
TP expression. Cancer cell overexpression was related to high
neovascularization regardless of fibroblast expression (P<0.0003).
However, high TP stromal fibroblast expression was directly related
to high neoangiogenesis, even when cancer cells were negatively
stained (P = 0.001), (Figure 1E andF). In that way, cases with strong
overexpression in cancercells and/or fibroblasts could be grouped in
acategory ofhighTPR, among which48% hadhighangiogenesis; in
contrast, only 12% of cases with low TPR had high vascularization
(P =0.0001).
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Degree of macrophage infiltration analysis
In Table 4 the degree of macrophage tumour infiltration (MI) is
analysed with respect to other parameters. No correlation was
found with cancer cell TP expression. A strong correlation
between high degree of MI and fibroblast TP overexpression was
found (P = 0.0003). Only 4 out of 17 (23%) cases with both
intense fibroblast and macrophage reactivity had a high vascular
grade, whereas 12 out of 18 (67%) cases with absence of
macrophage infiltration and strong fibroblast TP overexpression
had high angiogenesis (P = 0.02; Yates' continuity correction test).
The amount ofstroma was notrelated tomacrophage infiltration.
High fibroblast TPR was related to intense MI, regardless of the
amount of stroma (abundant, P=0.001; scarce, P= 0.008). High
macrophage infiltration was related to a low incidence of lymph
node metastases, but the significance was marginal (P = 0.04).
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Figure 3 Survival curves in different vascular grade (VG) categories
stratifying for cancer cell TP reactivity (CCR; A), for fibroblast TP reactivity
(FR; B) and for macrophage infiltration (Ml; C). (A)-, A, CCR-/LVG (81 pts);
- - -, B, CCR-/HVG (20 pts); ----, C, CCR+/LVG (19 pts); --, D, CCR+/HVG
(21 pts). A vs B, P = 0.001; AVSC, P = 0.004; AVSD, P = 0.001; B vs C vs D,
P = NS. (B) -, A, FR+/LVG (19 pts); ----, B, FR-/HVG (81 pts); -, C,
FR-/HVG (25 pts); - - -, D, FR+/HVG (16 pts). A vs B, P = 0.02; A vs C,
P = 0.0009; A vs D, P = 0.0005; B vs C, P = 0.02; B vs D, P = 0.004; C vs D,
P = 0.53. (C) -, A, HMI/LVG (27 pts); ----, B, LMI/LVG (73 pts); -, C,
LMI/HVG (32 pts); - - -, D, HMI/HVG (9 pts). A vs B, P= 0.77; C vs D,
P = 0.35
Overall survival analysis
Survival analysis showed that cancer cell TP overexpression was
related to poor prognosis (P = 0.005), whereas fibroblast TP over-
expression had no impact on survival (P = 0.8) (Figure 2A and B).
High total TPR defined worse prognosis (P = 0.03) compared with
low TPR cases (Figure 2C).
Stratifying for vascular grade, we found that low vascular grade
cases with cancer cell TP overexpression had a poorer prognosis,
similar to high vascular grade cases (P = 0.004) (Figure 3A). In
contrast, low vascular grade cases with high fibroblast TPR had an
excellent prognosis compared with low vascular grade cases with
negative fibroblasts (P = 0.02) (Figure 3b). Fibroblast reactivity
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was not of prognostic significance for high vascular grade cases.
The quantity of stroma did not define different prognostic groups
within the low or high vascular grade categories (P = 0.51). The
degree of macrophage infiltration was not related to prognosis in
either high or low vascular grade categories (Figure 3C).
We further stratified the group of patients with the best prog-
nosis (low vascular grade with cancer cells negative for TP),
taking into account the fibroblast reactivity and macrophage
infiltration. Fibroblast TP overexpression defined an excellent
prognosis (only one death out of 16 patients; P = 0.02). High
macrophage infiltration in the absence of fibroblast reactivity
defined a very poor prognosis (P = 0.02; Figure 4).
Multivariate analysis taking into account all the considered vari-
ables (T, N stage, grade, histology, vascular grade, cancer cell and
fibroblast TPR showed that vascular grade and histology were inde-
pendent prognostic indicators (P = 0.022 and 0.026 respectively).
Excluding N stage, which is not an inherent tumour factor and was
dependent on angiogenesis, multivariate analysis showed that the
only independent prognostic factor was the vascular grade (P =
0.001). In patients who were inoperable for medical or other
reasons, both N stage and vascular grade are difficult to assess.
Lymph node involvement often escapes CT or MRI scan diagnosis
and tiny bioptical material after bronchoscopy is impossible to
assess reliably for the angiogenesis status of the tumour. However,
diffuse strong cancer cell TP expression can be detected even in
bronchial biospies (Giatromanolaki et al, 1997). To assess a
possible role ofcancer cell TPR status in predicting the prognosis of
inoperable cases, we further examined a statistical model excluding
both N stage and vascular grade. We found that in this model cancer
cell TPR was the only independent prognostic variable (P = 0.01).
DISCUSSION
Although platelet-derived endothelial cell growth factor was
initially cloned as a novel non-heparin-binding angiogenic factor
present in platelets, this factor was subsequently shown to be TP
(Ishikawa et al, 1989; Usuki et al, 1989; Moghaddam et al, 1992).
Moghaddam et al (1995) recently showed that TP is angiogenic in
the rat subcutaneous sponge model, its activity being independent
ofbasic FGF. Not only did TP promote endothelial cell migration,
but cancer cells overexpressing the factor had a significantly faster
growth rate (Moghaddam et al, 1995). TP enzyme activity is also
essential for the metabolism of fluoropyrimidines, which suggests
thatTP-overexpressing tumours may be sensitive to antimetabolite
chemotherapy (Patterson et al, 1995).
In a recent study, we showed that tumour angiogenesis was the
most significant prognostic factor in stage I/II non-small-cell lung
cancer treated with surgery alone (Giatromanolaki et al, 1996a).
Moreover, we showed that TP tumour cell expression was associ-
ated with high angiogenesis and poor prognosis (Koukourakis et
al, 1997). The expression ofTP in breast cancer was also related to
high microvessel density in a study by Toi et al (1995). Fox et al
(1996) failed to confirm a net correlation of TP overexpression
with angiogenesis in breast cancer.
In a previous immunohistochemical study on TP expression in
non-small-cell lung cancer, we observed a high affinity of
macrophages to the antibody used as well as varying patterns of
fibroblast staining (Giatromanolaki et al, 1997). Stromal fibro-
blasts could or could not overexpress the TP independently from
cancer cell reactivity, whereas normal lung fibroblasts never
overexpressed the factor. In the present study, we evaluated the
meaning of these different tumour fibroblast and cancer cell
patterns of TP staining, taking into account the degree of TP-
positive macrophage infiltration. In this sequential series of 141
non-small-cell lung cancer cases, both cancer cell and stromal
fibroblast TP overexpression correlated with high intratumoral
neoangiogenesis.
Cancer cell overexpression was associated with high angio-
genesis in 54% of cases. Fibroblast overexpression in the absence
of cancer cell positivity was also associated with high vasculariza-
tion in 41% ofcases, whereas only 12% ofcases lacking cancer cell
or fibrobast TP expression were of high vascular grade. We distin-
guished two groups of patients with high and low total TPR, corre-
sponding to 50% and 12% probability, respectively, to correlate
with high angiogenesis. Such a grading could be useful in
predicting the degree of angiogenesis from biopsy material that is
impossible to analyse reliably for microvessel counting. In that
way, inoperable patients who are candidates for anti-angiogenic
therapy could be recruited. The observation that high TPR does not
define high angiogenesis in about halfofthe examined cases shows
that TP may co-operate with other angiogenic factors or oncogene
products for neovascularization to occur. Indeed, preliminary
results (Koukourakis et al, 1996) showed a possible involvement of
bcl-2 and c-erbB-2 oncoproteins in the TP-mediated angiogenic
activity. A VEGF and TP synergy in defining angiogenesis in
breast cancer has also been reported (Toi et al, 1995).
Survival analysis revealed that, although 'total thymidine phos-
phorylase reactivity' correlated with prognosis, cancer cell reac-
tivity was a stronger indicator. This was because fibroblast TPR
conferred an unusually good prognosis in low vascular grade cases
(94% 5-year survival), and therefore cancer cell reactivity alone
should be used as a more reliable prognostic indicator. In a multi-
variate model, excluding vascular grade and N stage, cancer cell
TPR CCR proved to be an independent prognostic parameter. This
may be used to assess prognosis in patients who are inoperable for
medical reasons, in whom only bronchoscopic material is available.
We also examined the role of macrophages. We found high
fibroblast TP expression reactivity with a high degree of
macrophage infiltration regardless of the amount of stroma.
Survival analysis showed that the degree of macrophage infiltra-
tion (per se) did not define different prognostic groups within the
low and high vascular grade groups. Fibroblast TP overexpression
determined a 5-year survival of up to 95% in the low vascular
grade group. Loss (or absence) of fibroblast TP activity together
with a high degree of macrophage infiltration in the low vascular
grade group was associated with a very poor prognosis (30% 5-
year survival). It may be that macrophages and fibroblasts have an
important role in the early steps of tumour pathogenesis by
inhibiting both angiogenesis and other mechanisms involved in the
metastatic process. This hypothesis is supported by a recent study
in breast cancer (Pupa et al, 1996), in which macrophage infiltra-
tion, although related to better prognosis, was also correlated with
C-erbB-2 positivity. C-erbB-2 protein is well known to disrupt cell
adhesion and to confer migratory abilities on cancer cells (Kanai et
al, 1995). Of interest, in a recent study of ours, c-erbB-2 onco-
protein correlated with low vascular grade (Giatromanolaki et al,
1996b; Koukourakis et al, 1996).
As TP-reactive stromal fibroblasts and high macrophage infiltra-
tion was a common feature in low vascular grade cases, an anti-
angiogenic role of combined macrophage and fibroblast activity in
non-small-cell lung cancer is suggested. In a recent study in breast
cancer, Leek et al (1996) showed that highly angiogenic areas were
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poorly populated with macrophages and macrophage-dense areas
were poorly vascularized, which is in accordance with our observa-
tion. It was recently shown (Di-Pietro et al, 1993) that activated
highly angiogenic macrophages produce the angiogenic inhibitor
thrombospondin-1, which shows a complex angiogenic role of
macrophages defined by positive and negative regulators. In a recent
study (Dong et al, 1997), angiostatin expression by Lewis lung
subcutaneously growing tumours required the presence of
macrophages and was directly correlated with macrophage metallo-
elastinolytic activity. Fibroblasts have also a role in angiogenesis
regulation. Dameron et al (1994) showed that fibroblasts also
control angiogenesis through p53-mediated thrombospondin-1 gene
regulation. It may be that activated fibroblasts represent a response
to cytokines produced by tumour-infiltrating macrophages.
Our observations may also have therapeutic implications,
suggesting that immunological manipulations that would restore
the fibroblast and macrophage equilibrium within the tumour
would have at least cytostatic activity. Interferon alpha (IFN-a) is
a well-known cytokine that induces the expression of thymidine
phosphorylase in cells (Schwartz et al, 1994). In a recent study,
we found an induction of thymidine phosphorylase in vivo in
lymphocytes of patients treated with escalating doses of IFN-cx
(unpublished data). On the other hand, granulocyte-macrophage
colony-stimulating factor (GM-CSF) is a widely used growth
factor that effectively stimulates the recovery of neutrophils and
macrophages in patients undergoing chemotherapy and has been
shown to be a potent activation signal for macrophages (Morissey
et al, 1989). It would be of interest to examine whether the
combination of IFN-oc and GM-CSF restores the fibroblast and
macrophage intratumoral activity and prevents tumourprogression
in refractory metastatic non-small-cell lung cancer. The recent
observation that GM-CSF-stimulated macrophages have enhanced
metalloelastinolytic activity, which is required for tumour angio-
statin production, further supports such a therapeutic approach
(Dong et al, 1997).
Briefly, we have provided evidence that fibroblasts and
macrophages may have an important role in the pathogenesis of
non-small-cell lung cancer. Their role is probably confined to early
pathogenetic steps before the appearance of the angiogenic and
migratory phenotype. The fact that not all angiogenic tumours are
lethal and that not all non-angiogenic tumours have a good prog-
nosis should not be attributed to random events, as factors such as
fibroblast or macrophage activity may have a definitive role.
Indeed, in our study, they defined groups with a 5-year survival as
high as 95%. Further investigation is required to clarify the role of
inflammatory cells in the angiogenic, migratory process and
prognosis in non-small-cell lung cancer.
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